262 related articles for article (PubMed ID: 17908926)
1. Bimodal degradation of MLL by SCFSkp2 and APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions.
Liu H; Cheng EH; Hsieh JJ
Genes Dev; 2007 Oct; 21(19):2385-98. PubMed ID: 17908926
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint.
Liu H; Takeda S; Kumar R; Westergard TD; Brown EJ; Pandita TK; Cheng EH; Hsieh JJ
Nature; 2010 Sep; 467(7313):343-6. PubMed ID: 20818375
[TBL] [Abstract][Full Text] [Related]
3. Disordered epigenetic regulation in MLL-related leukemia.
Zhang Y; Chen A; Yan XM; Huang G
Int J Hematol; 2012 Oct; 96(4):428-37. PubMed ID: 23054645
[TBL] [Abstract][Full Text] [Related]
4. The Cks1/Cks2 axis fine-tunes Mll1 expression and is crucial for MLL-rearranged leukaemia cell viability.
Grey W; Ivey A; Milne TA; Haferlach T; Grimwade D; Uhlmann F; Voisset E; Yu V
Biochim Biophys Acta Mol Cell Res; 2018 Jan; 1865(1):105-116. PubMed ID: 28939057
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.
Liu H; Westergard TD; Cashen A; Piwnica-Worms DR; Kunkle L; Vij R; Pham CG; DiPersio J; Cheng EH; Hsieh JJ
Cancer Cell; 2014 Apr; 25(4):530-42. PubMed ID: 24735925
[TBL] [Abstract][Full Text] [Related]
6. Frat2 mediates the oncogenic activation of Rac by MLL fusions.
Walf-Vorderwülbecke V; de Boer J; Horton SJ; van Amerongen R; Proost N; Berns A; Williams O
Blood; 2012 Dec; 120(24):4819-28. PubMed ID: 23074275
[TBL] [Abstract][Full Text] [Related]
7. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications.
Milne TA; Martin ME; Brock HW; Slany RK; Hess JL
Cancer Res; 2005 Dec; 65(24):11367-74. PubMed ID: 16357144
[TBL] [Abstract][Full Text] [Related]
8. MLL fusions: pathways to leukemia.
Liu H; Cheng EH; Hsieh JJ
Cancer Biol Ther; 2009 Jul; 8(13):1204-11. PubMed ID: 19729989
[TBL] [Abstract][Full Text] [Related]
9. Learning from mouse models of MLL fusion gene-driven acute leukemia.
Schwaller J
Biochim Biophys Acta Gene Regul Mech; 2020 Aug; 1863(8):194550. PubMed ID: 32320749
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias.
Grembecka J; Belcher AM; Hartley T; Cierpicki T
J Biol Chem; 2010 Dec; 285(52):40690-8. PubMed ID: 20961854
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathogenesis of MLL-associated leukemias.
Eguchi M; Eguchi-Ishimae M; Greaves M
Int J Hematol; 2005 Jul; 82(1):9-20. PubMed ID: 16105754
[TBL] [Abstract][Full Text] [Related]
12. Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors.
Ge M; Li D; Qiao Z; Sun Y; Kang T; Zhu S; Wang S; Xiao H; Zhao C; Shen S; Xu Z; Liu H
Oncogene; 2020 Sep; 39(36):5888-5901. PubMed ID: 32733069
[TBL] [Abstract][Full Text] [Related]
13. The E3 ubiquitin ligase Triad1 influences development of Mll-Ell-induced acute myeloid leukemia.
Wang H; Bei L; Shah CA; Huang W; Platanias LC; Eklund EA
Oncogene; 2018 May; 37(19):2532-2544. PubMed ID: 29459712
[TBL] [Abstract][Full Text] [Related]
14. The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation.
Amari K; Sasagawa S; Imayoshi N; Toda Y; Hosogi S; Imamura T; Ashihara E
Biochem Biophys Res Commun; 2022 Jan; 588():147-153. PubMed ID: 34954522
[TBL] [Abstract][Full Text] [Related]
15. A novel chromosomal inversion at 11q23 in infant acute myeloid leukemia fuses MLL to CALM, a gene that encodes a clathrin assembly protein.
Wechsler DS; Engstrom LD; Alexander BM; Motto DG; Roulston D
Genes Chromosomes Cancer; 2003 Jan; 36(1):26-36. PubMed ID: 12461747
[TBL] [Abstract][Full Text] [Related]
16. Activation of the Lysosome-Associated Membrane Protein LAMP5 by DOT1L Serves as a Bodyguard for MLL Fusion Oncoproteins to Evade Degradation in Leukemia.
Wang WT; Han C; Sun YM; Chen ZH; Fang K; Huang W; Sun LY; Zeng ZC; Luo XQ; Chen YQ
Clin Cancer Res; 2019 May; 25(9):2795-2808. PubMed ID: 30651276
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.
Borkin D; He S; Miao H; Kempinska K; Pollock J; Chase J; Purohit T; Malik B; Zhao T; Wang J; Wen B; Zong H; Jones M; Danet-Desnoyers G; Guzman ML; Talpaz M; Bixby DL; Sun D; Hess JL; Muntean AG; Maillard I; Cierpicki T; Grembecka J
Cancer Cell; 2015 Apr; 27(4):589-602. PubMed ID: 25817203
[TBL] [Abstract][Full Text] [Related]
18. Biphasic MLL takes helm at cell cycle control: implications in human mixed lineage leukemia.
Liu H; Takeda S; Cheng EH; Hsieh JJ
Cell Cycle; 2008 Feb; 7(4):428-35. PubMed ID: 18235233
[TBL] [Abstract][Full Text] [Related]
19. When epigenetics kills: MLL fusion proteins in leukemia.
Slany RK
Hematol Oncol; 2005 Mar; 23(1):1-9. PubMed ID: 16118769
[TBL] [Abstract][Full Text] [Related]
20. MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia.
Prange KHM; Mandoli A; Kuznetsova T; Wang SY; Sotoca AM; Marneth AE; van der Reijden BA; Stunnenberg HG; Martens JHA
Oncogene; 2017 Jun; 36(23):3346-3356. PubMed ID: 28114278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
